Management of Drug Toxicity in Mycobacterium Avium Complex Pulmonary Disease: An Expert Panel Survey

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2020 Sep 10

PMID 32910814

Citations 12

Authors

Jakko van Ingen

Stefano Aliberti

Claire Andrejak

James D Chalmers

Luigi R Codecasa

Charles L Daley

Naoki Hasegawa

David E Griffith

Wouter Hoefsloot

Gwen Huitt

Julie Jarand

Byung Woo Jhun

Michael R Loebinger

Theodore K Marras

Kozo Morimoto

Eva Polverino

Felix C Ringshausen

Miguel Santin

Rachel Thomson

Dirk Wagner

Richard J Wallace

Kevin L Winthrop

Jae-Joon Yim

Affiliations

Soon will be listed here.

Abstract

Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gastrointestinal upset. These opinions can provide assistance in individual patient management decisions.

Citing Articles

Management challenges and outcomes for non-tuberculous mycobacterial pulmonary disease.

De Man J, Adriaenssens N, Van Bleyenbergh P, Happaerts M, Andre E, Spriet I IJTLD Open. 2024; 1(7):332-334.

PMID: 39035424 PMC: 11257086. DOI: 10.5588/ijtldopen.24.0140.

Evaluation of a national multidisciplinary meeting for non-tuberculous mycobacterial disease.

Lemson A, Koster T, Carpaij N, Magis-Escurra C, Boeree M, Stemkens R IJTLD Open. 2024; 1(6):279-281.

PMID: 39021452 PMC: 11249658. DOI: 10.5588/ijtldopen.24.0044.

Growing from common ground: nontuberculous mycobacteria and bronchiectasis.

Van Braeckel E, Bosteels C Eur Respir Rev. 2024; 33(173).

PMID: 38960614 PMC: 11220627. DOI: 10.1183/16000617.0058-2024.

acquisition from hospital tap water: a genomic and epidemiologic analysis.

Baker A, Nick S, Jia F, Graves A, Warren B, Zavala S J Clin Microbiol. 2024; 62(6):e0014924.

PMID: 38690881 PMC: 11237794. DOI: 10.1128/jcm.00149-24.

Clofazimine as a substitute for rifampicin improves efficacy of pulmonary disease treatment in the hollow-fiber model.

Salillas S, Raaijmakers J, Aarnoutse R, Svensson E, Asouit K, van den Hombergh E Antimicrob Agents Chemother. 2024; 68(3):e0115723.

PMID: 38259101 PMC: 10916390. DOI: 10.1128/aac.01157-23.

References

Brown B, Griffith D, Girard W, Levin J, Wallace Jr R . Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis. 1997; 24(5):958-64. DOI: 10.1093/clinids/24.5.958. View

van Ingen J, Egelund E, Levin A, Totten S, Boeree M, Mouton J . The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012; 186(6):559-65. DOI: 10.1164/rccm.201204-0682OC. View

Marras T, Prevots D, Jamieson F, Winthrop K . Variable agreement among experts regarding Mycobacterium avium complex lung disease. Respirology. 2014; 20(2):348-51. PMC: 11037023. DOI: 10.1111/resp.12440. View

Kamii Y, Nagai H, Kawashima M, Matsuki M, Nagoshi S, Sato A . Adverse reactions associated with long-term drug administration in complex lung disease. Int J Tuberc Lung Dis. 2019; 22(12):1505-1510. DOI: 10.5588/ijtld.18.0171. View

Diel R, Nienhaus A, Ringshausen F, Richter E, Welte T, Rabe K . Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review. Chest. 2018; 153(4):888-921. DOI: 10.1016/j.chest.2018.01.024. View

Morimoto K, Namkoong H, Hasegawa N, Nakagawa T, Morino E, Shiraishi Y . Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. Ann Am Thorac Soc. 2016; 13(11):1904-1911. DOI: 10.1513/AnnalsATS.201604-246OC. View

Wallace Jr R, Brown-Elliott B, McNulty S, Philley J, Killingley J, Wilson R . Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014; 146(2):276-282. PMC: 4694082. DOI: 10.1378/chest.13-2538. View

Zweijpfenning S, Kops S, Magis-Escurra C, Boeree M, van Ingen J, Hoefsloot W . Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. Respir Med. 2017; 131:220-224. DOI: 10.1016/j.rmed.2017.08.031. View

Saukkonen J, Cohn D, Jasmer R, Schenker S, Jereb J, Nolan C . An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174(8):935-52. DOI: 10.1164/rccm.200510-1666ST. View

10.

Jeong B, Jeon K, Park H, Moon S, Kim S, Lee S . Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2016; 60(10):6076-83. PMC: 5038230. DOI: 10.1128/AAC.00770-16. View

11.

Jeong B, Jeon K, Park H, Kim S, Lee K, Huh H . Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2014; 191(1):96-103. DOI: 10.1164/rccm.201408-1545OC. View

12.

Griffith D, Eagle G, Thomson R, Aksamit T, Hasegawa N, Morimoto K . Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018; 198(12):1559-1569. DOI: 10.1164/rccm.201807-1318OC. View

13.

Griffith D, Brown-Elliott B, Langsjoen B, Zhang Y, Pan X, Girard W . Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006; 174(8):928-34. DOI: 10.1164/rccm.200603-450OC. View

14.

Griffith D, Brown-Elliott B, Shepherd S, Mclarty J, Griffith L, Wallace Jr R . Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2005; 172(2):250-3. DOI: 10.1164/rccm.200407-863OC. View